News and Events

News

All categories

Earnings

Press Release

All years

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

November 14, 2019

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

November 13, 2019

Affimed Announces Pricing of Public Offering of Common Shares

November 8, 2019

Affimed Announces Proposed Public Offering of Common Shares

November 7, 2019

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

November 7, 2019

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

November 7, 2019

Affimed Reports Progress on Key Clinical Development Programs

October 15, 2019

Affimed to Participate in Investor Conferences in September

August 28, 2019

Affimed Reports Second Quarter 2019 Financial and Operational Results

August 7, 2019

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

July 31, 2019

Events

All

Scientific

Investors

28Mar

Innate Killer Summit

March 28 - 30, 2023 (San Diego, USA)

14Apr

AACR Annual Meeting 2023

April 14 - 19, 2023 (Orlando, Florida)

23Apr

EBMT 49th Annual Meeting

April 23 - 26, 2023 (Paris, France)

Webcasts More events

News and Events

News and Events

See what’s new at Affimed

See what’s new at Affimed

News

Affimed Announces Third Quarter 2019 Financial Results and Corporate Update Conference Call on November 19, 2019

Affimed Announces Closing of Public Offering of Common Shares and Exercise of Underwriters’ Option to Purchase Additional Shares

Affimed Announces Pricing of Public Offering of Common Shares

Affimed Announces Proposed Public Offering of Common Shares

Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers

Affimed Highlights Progress on NK Cell Engager Collaboration with Genentech

Affimed Reports Progress on Key Clinical Development Programs

Affimed to Participate in Investor Conferences in September

Affimed Reports Second Quarter 2019 Financial and Operational Results

Affimed Announces Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 7, 2019

Events

Innate Killer Summit

AACR Annual Meeting 2023

EBMT 49th Annual Meeting